Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis
نویسندگان
چکیده
منابع مشابه
Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
InAL amyloidosis, amyloid fibril deposits, derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia, accumulate in extracellular tissues and damage vital organs.1 Novel therapies used in multiple myeloma2 can be effective inAL amyloidosis. Separately in the same issue of Blood, our group and the Mayo Clinic described similar results of phase 2 trials of the use of len...
متن کاملDaratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. Additional well-tolerated treatment options are needed. We present our retrospective experience of 25 consecutive previously tre...
متن کاملA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Immune-modulatory drugs are active in immunoglobulin light-chain amyloidosis and the addition of alkylating agents can potentiate their action. In this phase II prospective trial we used cyclophosphamide, lenalidomide and dexamethasone in the treatment of 21 patients who were refractory (n=13, 62%) or relapsed (n=8, 38%) after prior treatment including melphalan in all cases, bortezomib in 4 an...
متن کاملSingle-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality. We report induction of sustai...
متن کاملLenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage vital organs. Treatment regimens used in multiple myeloma can be effective in AL amyloidosis; however, patients with this disease often tolerate these regimens poorly because of multisystem organ dysfunction....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2014
ISSN: 0361-8609
DOI: 10.1002/ajh.23722